Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Stonestreet was diagnosed with type 2 diabetes in 2009, but kept it a secret. He told Business Insider why he's speaking out ...

Eric Stonestreet's life changed forever in two major ways. First, he landed his role in "Modern Family," a critically ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Shares of Eli Lilly ( LLY -10.79%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations, ...

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...